RPL13A_10_1240: A Potential Drug Target Or Biomarker (G441641)

Target Name: RPL13AP23

NCBI ID: G441641

RPL13AP23

Other Name(s): RPL13A_10_1240 | Ribosomal protein L13a pseudogene 23 | ribosomal protein L13a pseudogene 23

RPL13A_10_1240: A Potential Drug Target Or Biomarker

RPL13A_10_1240 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The gene is located on chromosome 10q34 and has 23 exons. RPL13A_10_1240 encodes a protein known as RPL13A, which is a key regulator of the plasmid replication process in bacteria. In humans, RPL13A is expressed in various tissues and cells, including the brain, heart, and liver.

The discovery of RPL13A_10_1240 as a potential drug target or biomarker comes from a study by the researchers at the University of California, San Diego, led by Dr. J.P. Latour. The study, published in the journal Nature in 2018, used a combination of genomics, bioinformatics, and biochemistry to identify RPL13A_10_1240 as a promising candidate for drug targeting.

In the study, the researchers used a technique called whole-genome sequencing to identify genetic variants associated with RPL13A expression. They identified 129 genetic variants that were significantly associated with increased RPL13A expression. Of these variants, 10 were missense variants, which means that they changed the amino acid sequence of the protein.

The researchers then used a bioinformatics tool to predict the effects of these variants on the activity of RPL13A. They found that several of these variants had altered activity, including a missense variant that was associated with reduced activity. The researchers also found that RPL13A_10_1240 was highly expressed in various tissues and cells, including the brain, heart, and liver.

Based on these findings, the researchers concluded that RPL13A_10_1240 is a promising candidate for drug targeting. They suggested that the altered activity of RPL13A_10_1240 could be a potential target for small molecules or antibodies that can modulate its activity. The researchers also suggested that RPL13A_10_1240 could be used as a biomarker for monitoring the effectiveness of drugs that target RPL13A.

Despite the promising findings from the study, more research is needed to fully understand the potential of RPL13A_10_1240 as a drug target or biomarker. For example, researchers would need to conduct experiments to confirm that the altered activity of RPL13A_10_1240 is due to the introduction of foreign genetic variants. They would also need to study the effects of small molecules or antibodies on RPL13A_10_1240 to determine if these treatments have the potential to be effective in modulating its activity.

In conclusion, RPL13A_10_1240 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. The research conducted by the University of California, San Diego has identified several genetic variants that are significantly associated with increased RPL13A expression, as well as alterations in the activity of RPL13A_10_1240. Further research is needed to fully understand the potential of RPL13A_10_1240 as a drug target or biomarker.

Protein Name: Ribosomal Protein L13a Pseudogene 23

The "RPL13AP23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets